Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis
Minami, T.; Tojo, H.; Shinomura, Y.; Komatsubara, T.; Matsuzawa, Y.; Okamoto, M.
American Journal of Gastroenterology 88(7): 1076-1080
1993
ISSN/ISBN: 0002-9270 PMID: 8317409 Document Number: 416089
The protein mass of group II phospholipase A-2 (PLA-2) levels were immunochemically measured in sera of 43 patients with Crohn's disease (CD), 43 patients with ulcerative colitis (UC), and 35 healthy volunteers, and compared with PLA-2 enzymatic activity. Serum immunoreactive group II PLA-2 (IR-PLA-2 II) levels of active CD patients were significantly higher than those of the controls and inactive CD patients. Serum IR-PLA-2 II levels were also significantly greater in patients with severe UC and moderate UC than in the controls and patients with mild UC. Serum IR-PLA-2 II levels were found to be closely correlated with serum PLA-2 activity in patients with CD and UC. Serum IR-PLA-2 II levels and PLA-2 activity decreased by antiinflammatory treatment in six patients with CD and two with UC. These results suggest that serum IR-PLA-2 II levels can be a useful parameter in the evaluation of disease activity of CD and UC, and that elevated PLA-2 enzymatic activity in sera of patients with CD and UC is attributable to increased protein concentration of group II PLA-2, in agreement with our previous results.